Regado Biosciences Inc (RGDO) 1.21 $RGDO
Venous (Vein) Thrombosis - Pipeline Review, H1 2015 Report Gives Vital Latest News and Deals
M2 - Mon Jun 08, 6:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rjcg3h/venous_vein) has announced the addition of the "Venous (Vein) Thrombosis - Pipeline Review, H1 2015" report to their offering. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Venous (Vein) Thrombosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Venous (Vein) Thrombosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Venous (Vein) Thrombosis pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Astellas Pharma Inc. - Bayer AG - Bristol-Myers Squibb Company - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Generex Biotechnology Corporation - Merrion Pharmaceuticals Plc - Regado Biosciences, Inc. For more information visit http://www.researchandmarkets.com/research/rj...enous_vein About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BMY: 56.92 (-0.47), RGDO: 1.21 (unch)
Global Venous Thromboembolism Therapeutics Pipeline Review, H1 2015 - 9 Companies & 10 Drug Profiles
M2 - Fri Jun 05, 8:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z3cbpk/venous) has announced the addition of the "Venous Thromboembolism - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bayer AG - Daiichi Sankyo Company, Limited - Gamma Therapeutics, Inc. - GlycoMimetics, Inc. - Green Cross Corporation - Isis Pharmaceuticals, Inc. - Portola Pharmaceuticals, Inc. - Regado Biosciences, Inc. - Sanofi Drug Profiles - betrixaban - edoxaban tosylate - Gammarin - GCC-2107 - GMI-1271 - ISIS-FXIRx - Lysimab - REG-2 - rivaroxaban - semuloparin For more information visit http://www.researchandmarkets.com/research/z3cbpk/venous
PTLA: 20.75 (+0.39), ISIS: 57.56 (-0.28), GLYC: 7.36 (-0.05), RGDO: 1.21 (unch)
Tobira Therapeutics Completes Financing and Merger with Regado Biosciences
PR Newswire - Mon May 04, 3:30PM CDT
Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and immuno-inflammatory diseases, announced today the completion of its merger with Regado Biosciences, Inc. (NASDAQ: RGDO, through May 4). In conjunction with the closing of the merger, Tobira raised $40 million of common stock from a combination of new investors and all current Tobira institutional investors, including the previously announced $13 million in debt that converted to common stock in this closing. Together with approximately $33 million net cash on Regado's balance sheet, the combined company has approximately $70 million in cash to advance clinical development of first-in-class dual CCR2/CCR5 inhibitor cenicriviroc (CVC), which is being evaluated in the Phase 2b CENTAUR clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH) and liver fibrosis.
TBRA: 4.91 (unch), RGDO: 1.21 (unch)
Tobira Therapeutics Highlights Presentations at The International Liver Congress 2015
PR Newswire - Wed Apr 08, 7:00AM CDT
Tobira Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, announced today presentations of new data for cenicriviroc (CVC) at "The International Liver Congress," a conference organized by the European Association for the Study of the Liver (EASL). The conference is being held April 22-26 in Vienna, Austria.
TBRA: 4.91 (unch), RGDO: 1.21 (unch)
Tobira Therapeutics Highlights Presentations at the AASLD's Industry Colloquium for Novel Targets and Therapies in Liver Disease
PR Newswire - Fri Mar 20, 6:30AM CDT
Tobira Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, announced today that it will be presenting at the "Industry Colloquium: Novel Targets and Therapies in Liver Disease" a conference organized by the American Association for the Study of Liver Disease (AASLD). The conference is being held today and tomorrow, March 21st, in Durham, NC.
TBRA: 4.91 (unch), RGDO: 1.21 (unch)
Tobira Therapeutics completes USD13m financing in support of development of CVC in non-alcoholic steatohepatitis
M2 - Tue Mar 10, 6:08AM CDT
Biopharmaceutical company Tobira Therapeutics revealed on Monday that it has completed a USD13m convertible note financing.
TBRA: 4.91 (unch), RGDO: 1.21 (unch)
Regado Biosciences (RGDO) Jumps: Stock Surges 20.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 8:11AM CDT
Regado Biosciences, Inc. (RGDO) was a big mover last session, as the company saw its shares rise over 20% on the day.
ANIP: 61.90 (+2.16), RGDO: 1.21 (unch)
Tobira Therapeutics Closes Financing to Support Development of CVC in Non-Alcoholic Steatohepatitis
PR Newswire - Mon Mar 09, 7:00AM CDT
Tobira Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, announced today that it has completed a $13 million convertible note financing. The funding will support Tobira's clinical program with cenicriviroc (CVC), its dual CCR2/CCR5 inhibitor targeting immuno-inflammation and fibrogenesis in non-alcoholic steatohepatitis (NASH), a disease associated with obesity and diabetes that often leads to liver cirrhosis. Abingworth LLP, Biotechnology Value Fund, L.P. and other affiliates of BVF Partners L.P. and Stonepine Capital Management LLC, in addition to all of Tobira's current investors, participated in the financing. Financial terms are not being disclosed at this time. The closing of the note financing and the investment by Tobira's current investors was contemplated by the previously announced merger agreement with Regado Biosciences. The merger is expected to close in the second quarter of 2015.
TBRA: 4.91 (unch), RGDO: 1.21 (unch)
Thromboembolism Therapeutics Pipeline Review 2015 - 10 Companies & 15 Drug Profiles
M2 - Tue Mar 03, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/s66bfv/thromboembolism) has announced the addition of the "Thromboembolism - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thromboembolism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bayer AG - Cereno Scientific AB - CSL Limited - Daiichi Sankyo Company, Limited - Gamma Therapeutics, Inc. - Green Cross Corporation - Isis Pharmaceuticals, Inc. - Portola Pharmaceuticals, Inc. - Regado Biosciences, Inc. - Sanofi Drug Profiles - betrixaban - C-3 - CSL-3F7 - edoxaban tosylate - Gammarin - GCC-2107 - ISIS-FXIRx - Lysimab - Protein for Thromboembolism and Blood Coagulation - REG-2 - rivaroxaban - semuloparin - Small Molecules to Inhibit HDAC for Thromboembolism - TAP-ANV - YG-001 For more information visit http://www.researchandmarkets.com/research/s6...boembolism
PTLA: 20.75 (+0.39), ISIS: 57.56 (-0.28), RGDO: 1.21 (unch)
Coronary Artery Disease Therapeutics Pipeline Market H1 2015 Research Report Available at RnRMarketResearch.com
PRWeb - Thu Feb 05, 7:31AM CST
The report "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease). Coronary artery disease (Ischemic Heart Disease) is the most common type of heart disease. Coronary artery disease is the tightening or blockage of the coronary arteries. A severe adequate blockage may cause a heart attack. Coronary artery disease (Ischemic Heart Disease) is the foremost cause of death in US, UK and globally. Most ischaemic heart disease is caused by atherosclerosis. However there are a number of risk factors.
CRME: 2.95 (-0.03), GILD: 77.44 (-0.94), PSTI: 1.65 (unch), MRK: 62.81 (+0.02), AZN: 32.66 (-0.15), EGRX: 58.66 (-1.09), BMY: 56.92 (-0.47), RGDO: 1.21 (unch)
Intercept Pharmaceuticals' OCA Now Breakthrough Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 3:54PM CST
Intercept Pharmaceuticals, Inc.'s (ICPT) obeticholic acid (OCA) received Breakthrough Therapy designation from the FDA for nonalcoholic steatohepatitis (NASH).
MNK: 75.12 (+0.58), ICPT: 147.75 (-0.56), RGDO: 1.21 (unch), CELG: 106.06 (-0.68)
SurModics Beats on Q1 Earnings, Reaffirms 2015 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 9:20AM CST
SurModics, Inc.'s first-quarter fiscal 2015 (ended Dec 31, 2014) adjusted earnings of 25 cents per share beat the Zacks Consensus Estimate by 4 cents.
SRDX: 28.70 (+0.23), AMAG: 23.69 (-0.14), RGDO: 1.21 (unch), CELG: 106.06 (-0.68)
Alexion Misses on Q4 Earnings, 2015 Outlook Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 3:20PM CST
Alexion Pharmaceuticals' (ALXN) fourth-quarter 2014 earnings (including stock-based compensation expense) of $1.15 per share.
ALXN: 124.96 (-0.90), AMAG: 23.69 (-0.14), RGDO: 1.21 (unch), CELG: 106.06 (-0.68)
BioDelivery Signs Agreement with Meda for Onsolis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 3:07PM CST
BioDelivery (BDSI) entered into an agreement with Meda to obtain marketing authorizations for Onsolis.
BDSI: 2.37 (-0.07), OPHT: 52.63 (-0.18), RGDO: 1.21 (unch), CELG: 106.06 (-0.68)
Celgene Q4 Earnings & Revenues In Line, Revlimid Sales Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 9:51AM CST
Celgene Corporation (CELG) reported fourth-quarter 2014 earnings of 88 cents per share.
ALXN: 124.96 (-0.90), AMAG: 23.69 (-0.14), RGDO: 1.21 (unch), CELG: 106.06 (-0.68)
Synageva Starts Dosing in Phase I/II Study for Sanfilippo B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 5:25PM CST
Synageva BioPharma Corp. (GEVA) has commenced patient dosing in a phase I/II study on SBC-103 for mucopolysaccharidosis IIIB (also known as Sanfilippo B syndrome).
BMRN: 94.18 (+0.29), GEVA: 238.60 (+2.80), RGDO: 1.21 (unch), CELG: 106.06 (-0.68)
Strength Seen in ZIOPHARM (ZIOP): Stock Rises 11.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 8:25AM CST
ZIOPHARM (ZIOP) was a big mover last session, with its shares rising roughly 12% on the day.
ZIOP: 5.00 (-0.07), RGDO: 1.21 (unch)
Venous (Vein) Thrombosis - Pipeline Review, H1 2015 Report Gives Vital Latest News and Deals
M2 - Mon Jun 08, 6:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rjcg3h/venous_vein) has announced the addition of the "Venous (Vein) Thrombosis - Pipeline Review, H1 2015" report to their offering. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Venous (Vein) Thrombosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Venous (Vein) Thrombosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Venous (Vein) Thrombosis pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Astellas Pharma Inc. - Bayer AG - Bristol-Myers Squibb Company - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Generex Biotechnology Corporation - Merrion Pharmaceuticals Plc - Regado Biosciences, Inc. For more information visit http://www.researchandmarkets.com/research/rj...enous_vein About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BMY: 56.92 (-0.47), RGDO: 1.21 (unch)
Global Venous Thromboembolism Therapeutics Pipeline Review, H1 2015 - 9 Companies & 10 Drug Profiles
M2 - Fri Jun 05, 8:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z3cbpk/venous) has announced the addition of the "Venous Thromboembolism - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bayer AG - Daiichi Sankyo Company, Limited - Gamma Therapeutics, Inc. - GlycoMimetics, Inc. - Green Cross Corporation - Isis Pharmaceuticals, Inc. - Portola Pharmaceuticals, Inc. - Regado Biosciences, Inc. - Sanofi Drug Profiles - betrixaban - edoxaban tosylate - Gammarin - GCC-2107 - GMI-1271 - ISIS-FXIRx - Lysimab - REG-2 - rivaroxaban - semuloparin For more information visit http://www.researchandmarkets.com/research/z3cbpk/venous
PTLA: 20.75 (+0.39), ISIS: 57.56 (-0.28), GLYC: 7.36 (-0.05), RGDO: 1.21 (unch)
Tobira Therapeutics Completes Financing and Merger with Regado Biosciences
PR Newswire - Mon May 04, 3:30PM CDT
Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and immuno-inflammatory diseases, announced today the completion of its merger with Regado Biosciences, Inc. (NASDAQ: RGDO, through May 4). In conjunction with the closing of the merger, Tobira raised $40 million of common stock from a combination of new investors and all current Tobira institutional investors, including the previously announced $13 million in debt that converted to common stock in this closing. Together with approximately $33 million net cash on Regado's balance sheet, the combined company has approximately $70 million in cash to advance clinical development of first-in-class dual CCR2/CCR5 inhibitor cenicriviroc (CVC), which is being evaluated in the Phase 2b CENTAUR clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH) and liver fibrosis.
TBRA: 4.91 (unch), RGDO: 1.21 (unch)
Tobira Therapeutics Highlights Presentations at The International Liver Congress 2015
PR Newswire - Wed Apr 08, 7:00AM CDT
Tobira Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, announced today presentations of new data for cenicriviroc (CVC) at "The International Liver Congress," a conference organized by the European Association for the Study of the Liver (EASL). The conference is being held April 22-26 in Vienna, Austria.
TBRA: 4.91 (unch), RGDO: 1.21 (unch)
Tobira Therapeutics Highlights Presentations at the AASLD's Industry Colloquium for Novel Targets and Therapies in Liver Disease
PR Newswire - Fri Mar 20, 6:30AM CDT
Tobira Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, announced today that it will be presenting at the "Industry Colloquium: Novel Targets and Therapies in Liver Disease" a conference organized by the American Association for the Study of Liver Disease (AASLD). The conference is being held today and tomorrow, March 21st, in Durham, NC.
TBRA: 4.91 (unch), RGDO: 1.21 (unch)
Tobira Therapeutics completes USD13m financing in support of development of CVC in non-alcoholic steatohepatitis
M2 - Tue Mar 10, 6:08AM CDT
Biopharmaceutical company Tobira Therapeutics revealed on Monday that it has completed a USD13m convertible note financing.
TBRA: 4.91 (unch), RGDO: 1.21 (unch)
Regado Biosciences (RGDO) Jumps: Stock Surges 20.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 8:11AM CDT
Regado Biosciences, Inc. (RGDO) was a big mover last session, as the company saw its shares rise over 20% on the day.
ANIP: 61.90 (+2.16), RGDO: 1.21 (unch)
Tobira Therapeutics Closes Financing to Support Development of CVC in Non-Alcoholic Steatohepatitis
PR Newswire - Mon Mar 09, 7:00AM CDT
Tobira Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, announced today that it has completed a $13 million convertible note financing. The funding will support Tobira's clinical program with cenicriviroc (CVC), its dual CCR2/CCR5 inhibitor targeting immuno-inflammation and fibrogenesis in non-alcoholic steatohepatitis (NASH), a disease associated with obesity and diabetes that often leads to liver cirrhosis. Abingworth LLP, Biotechnology Value Fund, L.P. and other affiliates of BVF Partners L.P. and Stonepine Capital Management LLC, in addition to all of Tobira's current investors, participated in the financing. Financial terms are not being disclosed at this time. The closing of the note financing and the investment by Tobira's current investors was contemplated by the previously announced merger agreement with Regado Biosciences. The merger is expected to close in the second quarter of 2015.
TBRA: 4.91 (unch), RGDO: 1.21 (unch)
Thromboembolism Therapeutics Pipeline Review 2015 - 10 Companies & 15 Drug Profiles
M2 - Tue Mar 03, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/s66bfv/thromboembolism) has announced the addition of the "Thromboembolism - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thromboembolism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bayer AG - Cereno Scientific AB - CSL Limited - Daiichi Sankyo Company, Limited - Gamma Therapeutics, Inc. - Green Cross Corporation - Isis Pharmaceuticals, Inc. - Portola Pharmaceuticals, Inc. - Regado Biosciences, Inc. - Sanofi Drug Profiles - betrixaban - C-3 - CSL-3F7 - edoxaban tosylate - Gammarin - GCC-2107 - ISIS-FXIRx - Lysimab - Protein for Thromboembolism and Blood Coagulation - REG-2 - rivaroxaban - semuloparin - Small Molecules to Inhibit HDAC for Thromboembolism - TAP-ANV - YG-001 For more information visit http://www.researchandmarkets.com/research/s6...boembolism
PTLA: 20.75 (+0.39), ISIS: 57.56 (-0.28), RGDO: 1.21 (unch)
Coronary Artery Disease Therapeutics Pipeline Market H1 2015 Research Report Available at RnRMarketResearch.com
PRWeb - Thu Feb 05, 7:31AM CST
The report "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease). Coronary artery disease (Ischemic Heart Disease) is the most common type of heart disease. Coronary artery disease is the tightening or blockage of the coronary arteries. A severe adequate blockage may cause a heart attack. Coronary artery disease (Ischemic Heart Disease) is the foremost cause of death in US, UK and globally. Most ischaemic heart disease is caused by atherosclerosis. However there are a number of risk factors.
CRME: 2.95 (-0.03), GILD: 77.44 (-0.94), PSTI: 1.65 (unch), MRK: 62.81 (+0.02), AZN: 32.66 (-0.15), EGRX: 58.66 (-1.09), BMY: 56.92 (-0.47), RGDO: 1.21 (unch)
Intercept Pharmaceuticals' OCA Now Breakthrough Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 3:54PM CST
Intercept Pharmaceuticals, Inc.'s (ICPT) obeticholic acid (OCA) received Breakthrough Therapy designation from the FDA for nonalcoholic steatohepatitis (NASH).
MNK: 75.12 (+0.58), ICPT: 147.75 (-0.56), RGDO: 1.21 (unch), CELG: 106.06 (-0.68)
SurModics Beats on Q1 Earnings, Reaffirms 2015 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 9:20AM CST
SurModics, Inc.'s first-quarter fiscal 2015 (ended Dec 31, 2014) adjusted earnings of 25 cents per share beat the Zacks Consensus Estimate by 4 cents.
SRDX: 28.70 (+0.23), AMAG: 23.69 (-0.14), RGDO: 1.21 (unch), CELG: 106.06 (-0.68)
Alexion Misses on Q4 Earnings, 2015 Outlook Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 3:20PM CST
Alexion Pharmaceuticals' (ALXN) fourth-quarter 2014 earnings (including stock-based compensation expense) of $1.15 per share.
ALXN: 124.96 (-0.90), AMAG: 23.69 (-0.14), RGDO: 1.21 (unch), CELG: 106.06 (-0.68)
BioDelivery Signs Agreement with Meda for Onsolis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 3:07PM CST
BioDelivery (BDSI) entered into an agreement with Meda to obtain marketing authorizations for Onsolis.
BDSI: 2.37 (-0.07), OPHT: 52.63 (-0.18), RGDO: 1.21 (unch), CELG: 106.06 (-0.68)
Celgene Q4 Earnings & Revenues In Line, Revlimid Sales Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 9:51AM CST
Celgene Corporation (CELG) reported fourth-quarter 2014 earnings of 88 cents per share.
ALXN: 124.96 (-0.90), AMAG: 23.69 (-0.14), RGDO: 1.21 (unch), CELG: 106.06 (-0.68)
Synageva Starts Dosing in Phase I/II Study for Sanfilippo B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 5:25PM CST
Synageva BioPharma Corp. (GEVA) has commenced patient dosing in a phase I/II study on SBC-103 for mucopolysaccharidosis IIIB (also known as Sanfilippo B syndrome).
BMRN: 94.18 (+0.29), GEVA: 238.60 (+2.80), RGDO: 1.21 (unch), CELG: 106.06 (-0.68)
Strength Seen in ZIOPHARM (ZIOP): Stock Rises 11.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 8:25AM CST
ZIOPHARM (ZIOP) was a big mover last session, with its shares rising roughly 12% on the day.
ZIOP: 5.00 (-0.07), RGDO: 1.21 (unch)
